Literature DB >> 26902523

4D-Listmode-PET-CT and 4D-CT for optimizing PTV margins in gastric lymphoma : Determination of intra- and interfractional gastric motion.

Gabriele Reinartz1, Uwe Haverkamp2, Ramona Wullenkord2, Philipp Lehrich2, Jan Kriz2, Florian Büther3, Klaus Schäfers3,4, Michael Schäfers3,5,4, Hans Theodor Eich2.   

Abstract

PURPOSE: New imaging protocols for radiotherapy in localized gastric lymphoma were evaluated to optimize planning target volume (PTV) margin and determine intra-/interfractional variation of the stomach.
METHODS: Imaging of 6 patients was explored prospectively. Intensity-modulated radiotherapy (IMRT) planning was based on 4D/3D imaging of computed tomography (CT) and positron-emission tomography (PET)-CT. Static and motion gross tumor volume (sGTV and mGTV, respectively) were distinguished by defining GTV (empty stomach), clinical target volume (CTV = GTV + 5 mm margin), PTV (GTV + 10/15/20/25 mm margins)  plus paraaortic lymph nodes and proximal duodenum. Overlap of 4D-Listmode-PET-based mCTV with 3D-CT-based PTV (increasing margins) and V95/D95 of mCTV were evaluated. Gastric shifts were determined using online cone-beam CT. Dose contribution to organs at risk was assessed.
RESULTS: The 4D data demonstrate considerable intra-/interfractional variation of the stomach, especially along the vertical axis. Conventional 3D-CT planning utilizing advancing PTV margins of 10/15/20/25 mm resulted in rising dose coverage of mCTV (4D-Listmode-PET-Summation-CT) and rising D95 and V95 of mCTV. A PTV margin of 15 mm was adequate in 3 of 6 patients, a PTV margin of 20 mm was adequate in 4 of 6 patients, and a PTV margin of 25 mm was adequate in 5 of 6 patients.
CONCLUSION: IMRT planning based on 4D-PET-CT/4D-CT together with online cone-beam CT is advisable to individualize the PTV margin and optimize target coverage in gastric lymphoma.

Entities:  

Keywords:  4D computed tomography; Cone-beam computed tomography; Gastric lymphoma; Intensity-modulated radiotherapy; Planning target volume margin; Positron-emission tomography

Mesh:

Year:  2016        PMID: 26902523     DOI: 10.1007/s00066-016-0949-0

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  16 in total

1.  Usefulness of 4D-CT for radiation treatment planning of gastric MZBCL/MALT.

Authors:  Munetaka Matoba; Kiyotaka Oota; Ichiro Toyoda; Masataka Kitadate; Naoto Watanabe; Hisao Tonami
Journal:  J Radiat Res       Date:  2012-03-15       Impact factor: 2.724

Review 2.  Radiation therapy for localized low-grade non-Hodgkin's lymphomas.

Authors:  Richard W Tsang; Mary K Gospodarowicz
Journal:  Hematol Oncol       Date:  2005-03       Impact factor: 5.271

3.  Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation alone.

Authors:  N R Schechter; C S Portlock; J Yahalom
Journal:  J Clin Oncol       Date:  1998-05       Impact factor: 44.544

4.  Outcome and quality of life favour a conservative treatment of patients with primary gastric lymphoma.

Authors:  W Fischbach; S Schramm; E Goebeler
Journal:  Z Gastroenterol       Date:  2011-04-07       Impact factor: 2.000

5.  Respiratory gated [18F]FDG PET/CT for target volume delineation in stereotactic radiation treatment of liver metastases.

Authors:  R A Bundschuh; N Andratschke; J Dinges; M N Duma; S T Astner; M Brügel; S I Ziegler; M Molls; M Schwaiger; M Essler
Journal:  Strahlenther Onkol       Date:  2012-03-24       Impact factor: 3.621

6.  Long-term outcome in localized extranodal mucosa-associated lymphoid tissue lymphomas treated with radiotherapy.

Authors:  Jayant S Goda; Mary Gospodarowicz; Melania Pintilie; Woodrow Wells; David C Hodgson; Alexander Sun; Micheal Crump; Richard W Tsang
Journal:  Cancer       Date:  2010-08-15       Impact factor: 6.860

7.  Detection of respiratory tumour motion using intrinsic list mode-driven gating in positron emission tomography.

Authors:  Florian Büther; Iris Ernst; Mohammad Dawood; Peter Kraxner; Michael Schäfers; Otmar Schober; Klaus P Schäfers
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-07-06       Impact factor: 9.236

8.  Stereotactic body radiotherapy for pulmonary metastases. Prognostic factors and adverse respiratory events.

Authors:  T Inoue; R-J Oh; H Shiomi; N Masai; H Miura
Journal:  Strahlenther Onkol       Date:  2013-02-20       Impact factor: 3.621

9.  Target volume coverage and dose to organs at risk in prostate cancer patients. Dose calculation on daily cone-beam CT data sets.

Authors:  P Hüttenrauch; M Witt; D Wolff; S Bosold; R Engenhart-Cabillic; J Sparenberg; H Vorwerk; K Zink
Journal:  Strahlenther Onkol       Date:  2014-01-16       Impact factor: 3.621

10.  Interfractional variability in intensity-modulated radiotherapy of prostate cancer with or without thermoplastic pelvic immobilization.

Authors:  J A Lee; C Y Kim; Y J Park; W S Yoon; N K Lee; D S Yang
Journal:  Strahlenther Onkol       Date:  2013-11-08       Impact factor: 3.621

View more
  3 in total

1.  Radiotherapy for extramedullary leukaemic manifestation (Chloroma).

Authors:  Michael Oertel; Khaled Elsayad; Uwe Haverkamp; Matthias Stelljes; Hans Theodor Eich
Journal:  Strahlenther Onkol       Date:  2017-11-16       Impact factor: 3.621

2.  Favorable radiation field decrease in gastric marginal zone lymphoma : Experience of the German Study Group on Gastrointestinal Lymphoma (DSGL).

Authors:  Gabriele Reinartz; Regina P Pyra; Georg Lenz; Rüdiger Liersch; Georg Stüben; Oliver Micke; Kay Willborn; Clemens F Hess; Andreas Probst; Rainer Fietkau; Ralf Jany; Jürgen Schultze; Christian Rübe; Carsten Hirt; Wolfgang Fischbach; Martin Bentz; Severin Daum; Christiane Pott; Markus Tiemann; Peter Möller; Andreas Neubauer; Martin Wilhelm; Normann Willich; Wolfgang E Berdel; Hans T Eich
Journal:  Strahlenther Onkol       Date:  2019-03-11       Impact factor: 3.621

Review 3.  Development of Organ-Preserving Radiation Therapy in Gastric Marginal Zone Lymphoma.

Authors:  Daniel Rolf; Gabriele Reinartz; Stephan Rehn; Christopher Kittel; Hans Theodor Eich
Journal:  Cancers (Basel)       Date:  2022-02-10       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.